Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line
10:32am, Friday, 04'th Aug 2023
Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.
Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript
11:55am, Thursday, 03'rd Aug 2023
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2023 Results Conference Call August 3, 2023 8:00 AM ET Company Participants Christopher Taylor - Vice President of Investor Relations Brian Goff - Chief E
Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet
11:17am, Monday, 17'th Jul 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionab
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
07:00am, Thursday, 13'th Jul 2023
CAMBRIDGE, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the
Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?
11:22am, Wednesday, 28'th Jun 2023
Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint
03:03pm, Tuesday, 27'th Jun 2023
Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed with the phase III portion of the investigation.
Why Shares of Schrödinger Rose This Week
01:20pm, Friday, 16'th Jun 2023
Schrödinger focuses on drug discovery using an AI platform. The company has already helped bring two therapies to market.
Wall Street Analysts Believe Agios Pharmaceuticals (AGIO) Could Rally 39.16%: Here's is How to Trade
10:58am, Monday, 12'th Jun 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionab
Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect?
11:01am, Thursday, 25'th May 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 34.8% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionab
Agios Pharmaceuticals: Good Execution, A Good Deal Of Cash, Some Hurdles
11:02am, Wednesday, 24'th May 2023
Agios Pharmaceuticals, Inc. has done well after its pivot to rare diseases. The move has also generated a huge amount of cash.
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
10:00am, Thursday, 11'th May 2023
– Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND ® (mitapivat) on Hemoglobin, Hemolysi
Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know
11:27am, Tuesday, 09'th May 2023
The consensus price target hints at a 42.5% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y
12:09pm, Friday, 05'th May 2023
Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
07:00am, Tuesday, 25'th Apr 2023
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced th
Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
07:00am, Thursday, 13'th Apr 2023
CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced th
